LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), today announced that preliminary results from the Phase 3 trial (SYMMETRYSM) of elesclomol in metastatic melanoma will be the subject of an oral presentation in the Melanoma session at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida.
